全文获取类型
收费全文 | 38482篇 |
免费 | 3705篇 |
国内免费 | 2807篇 |
专业分类
耳鼻咽喉 | 314篇 |
儿科学 | 551篇 |
妇产科学 | 501篇 |
基础医学 | 3969篇 |
口腔科学 | 663篇 |
临床医学 | 4916篇 |
内科学 | 5281篇 |
皮肤病学 | 363篇 |
神经病学 | 1660篇 |
特种医学 | 1620篇 |
外国民族医学 | 12篇 |
外科学 | 4192篇 |
综合类 | 7415篇 |
现状与发展 | 8篇 |
一般理论 | 3篇 |
预防医学 | 2894篇 |
眼科学 | 792篇 |
药学 | 4178篇 |
41篇 | |
中国医学 | 2524篇 |
肿瘤学 | 3097篇 |
出版年
2024年 | 134篇 |
2023年 | 569篇 |
2022年 | 1419篇 |
2021年 | 1739篇 |
2020年 | 1378篇 |
2019年 | 1104篇 |
2018年 | 1130篇 |
2017年 | 1200篇 |
2016年 | 1110篇 |
2015年 | 1696篇 |
2014年 | 2084篇 |
2013年 | 2045篇 |
2012年 | 2805篇 |
2011年 | 3243篇 |
2010年 | 2263篇 |
2009年 | 1898篇 |
2008年 | 2263篇 |
2007年 | 2296篇 |
2006年 | 2128篇 |
2005年 | 1940篇 |
2004年 | 1491篇 |
2003年 | 1413篇 |
2002年 | 1227篇 |
2001年 | 1061篇 |
2000年 | 938篇 |
1999年 | 795篇 |
1998年 | 447篇 |
1997年 | 511篇 |
1996年 | 339篇 |
1995年 | 298篇 |
1994年 | 237篇 |
1993年 | 189篇 |
1992年 | 230篇 |
1991年 | 213篇 |
1990年 | 183篇 |
1989年 | 165篇 |
1988年 | 136篇 |
1987年 | 137篇 |
1986年 | 120篇 |
1985年 | 76篇 |
1984年 | 50篇 |
1983年 | 28篇 |
1982年 | 19篇 |
1981年 | 17篇 |
1980年 | 25篇 |
1979年 | 45篇 |
1978年 | 22篇 |
1976年 | 12篇 |
1975年 | 18篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
3.
4.
5.
目的:通过3D打印的方法制备的不同重量比例的纳米羟基磷灰石/聚乳酸/聚乙烯醇(n-HA/PLA/PVA)复合膜,并对其相关性能检测。方法:采用3D打印技术制备不同重量比例的n-HA/PLA/PVA复合膜,分别为PLA/PVA复合膜、15%n-HA/PLA/PVA复合膜、50%n-HA/PLA/PVA复合膜、75%n-HA/PLA/PVA复合膜。扫描电镜下观察各组膜形态,对其力学性能、细胞毒性及动物实验相应指标进行检测。结果:扫描电镜下观察,n-HA/PLA/PVA复合膜呈现三维网状结构,各材料间相互结合,孔隙分布不均,大小不一。随着n-HA质量浓度的提高,电镜下见各材料间孔隙逐渐减小,形成结构均匀的复合膜。力学性能及吸水率检测中,随着nHA含量的增加,n-HA/PLA/PVA复合膜的拉伸强度及吸水率呈下降趋势;细胞毒性检测,不同比例复合膜的细胞增殖率无明显差别,无细胞毒性。动物实验测量牙周菌斑指数及龈沟出血指数未发现不同比例n-HA/PLA/PVA复合膜有统计学差异。结论:3D打印不同比例的n-HA/PLA/PVA复合膜具有良好的物理性能和细胞生物相容性,n-HA比例更高的复合膜可能具有更好的物理性能及良好的生物相容性。 相似文献
6.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
7.
HIV-1 infection usually leads to systemic chronic inflammation that is associated with gut microbial translocation. The recently defined group 3 innate lymphoid cells (ILC3s) are critical for maintenance of intestinal barrier function; however, it is not clear whether and how HIV-1 infection influences the function of these cells. In this issue of the JCI, Zhang and colleagues present compelling evidence that the survival and function of ILC3s are dramatically impaired by HIV-1 infection. The authors provide evidence that HIV-1 infection induces persistent activation of plasmacytoid dendritic cells (pDCs) and production of type I IFNs, which together increase expression of death receptor CD95 on ILC3s and thereby promote subsequent ILC3 apoptosis. Together, these results identify a mechanism that explains the impaired intestinal barrier function that results from chronic HIV-1 infection and shed light on the role of pDCs in HIV-1 immunopathogenesis and therapy. 相似文献
8.
9.
10.
目的 观察互动式歌唱表演对轻中度阿尔茨海默病(AD)患者抑郁、精神行为症状及运动训练参与率的影响。方法 选取符合入组条件≥60周岁AD患者63例,随机分为研究组(31例)和对照组(32例)。所有受试患者常规药物治疗及常规运动训练,对照组接受被动性音乐治疗,研究组接受以互动歌唱为主的主动性音乐治疗,1次/d,每次1小时,每周训练5天,持续干预6个月。于治疗前、治疗1个月后、治疗3个月后、治疗6个月后分别采用康奈尔痴呆抑郁量表(CSDD)评分、阿尔茨海默病病理行为(BEHAVE AD)评分、参与率进行评估。结果 治疗1个月、3个月后,研究组CSDD评分较治疗前均降低(P<0.05);治疗6个月后,研究组患者CSDD评分较治疗前、治疗1个月、3个月后均显著降低(P<0.05),且与对照组比较差异有统计学意义(P<0.05)。治疗1个月、3个月后,研究组BEHAVE AD评分较治疗前均降低(P<0.05);治疗6个月后,研究组患者BEHAVE AD评分较治疗前、治疗1个月、3个月后均显著降低(P<0.05),且与对照组比较差异有统计学意义(P<0.05)。治疗6个月后,两组运动训练参与率组间比较差异有统计学意义(P<0.05)。结论 互动式歌唱表演可能对改善轻中度AD患者的抑郁和精神行为症状有着积极的疗效,同时对提高受试者运动训练的参与率可能有着更积极的疗效。 相似文献